September 2026 Research Update

This month added a clearer picture of how low alkaline phosphatase on routine lab work can be used as a practical starting point to find children who may have hypophosphatasia, and to separate confirmed cases from carriers. The study showed that combining repeat low lab values with gene testing and a vitamin B6-related blood marker could identify a range of outcomes, from confirmed hypophosphatasia to symptom-free carrier status. This matters because hypophosphatasia can look different from child to child, and a structured pathway may reduce missed or delayed recognition in settings where low alkaline phosphatase is already being measured. [1]

In this screening group of 339 children with low alkaline phosphatase, genetic testing found clinically relevant ALPL variants in 114 children, which then led to 32 confirmed hypophosphatasia cases and 57 asymptomatic carriers. The same work also reported 25 children labeled as suspected cases, showing that some children fall into a gray zone where the genetic and clinical picture is not fully settled. The researchers also used lab-based functional testing to help reclassify 3 previously uncertain gene variants as likely disease-causing, which helps explain why some results are initially hard to interpret. [1]

Among the milder pediatric cases identified, dental differences and slowed growth were reported as common. Neurobehavioral concerns, including ADHD and tic disorders, were also observed in this screened population, although the study did not establish whether hypophosphatasia causes these issues. For families, the main added understanding is that the features noticed in milder childhood hypophosphatasia may extend beyond bones and teeth, but the strength and meaning of those links still need more confirmation. [1]

For patients and caregivers, this work mainly adds to understanding of diagnosis rather than changing treatment. It supports the idea that persistently low alkaline phosphatase can be a useful flag that prompts a more complete evaluation, and that genetic testing may identify both affected children and symptom-free carriers within the same screening pathway. What remains uncertain is how well this exact approach would work outside one hospital setting, and how to interpret children who fall into the "suspected" category. This may matter now for awareness and future research on better, earlier identification, especially for families dealing with dental problems or growth concerns where the cause is unclear.

This month provided an early but more concrete signal that hypophosphatasia may involve immune system differences, not only bone and tooth mineralization. In a Spanish adult cohort, immune cells from people with hypophosphatasia showed broadly reduced surface alkaline phosphatase compared with controls, alongside shifts in some immune cell subtypes. The same report described a high frequency of immune-mediated inflammatory diseases in the hypophosphatasia group, with lab differences that tracked with that diagnosis. This matters because it points to possible biological links that could be explored to better explain symptoms some patients experience. [2]

Compared with matched healthy controls, people with hypophosphatasia had lower alkaline phosphatase expression across several white blood cell types, including T cells and B cells. The study also described changes such as a higher ratio of one monocyte subtype (CD16-positive relative to CD14-positive), suggesting a different immune "mix" in circulation. These measurements do not prove a cause, but they help clarify that the enzyme affected in hypophosphatasia can be measured on immune cells and appears reduced broadly in this condition. [2]

Immune-mediated inflammatory diseases were reported in 46.8% of the adults with hypophosphatasia in this cohort, and those individuals tended to have lower blood alkaline phosphatase and higher fecal calprotectin (a stool marker of gut inflammation). In a smaller subgroup with detailed immune testing, immune-mediated inflammatory disease status was linked to fewer alkaline phosphatase-positive B cells and differences in CD8 cells within an NK-enriched cell population. The study proposed possible immune-regulating roles for the enzyme, but it did not test whether the enzyme changes actually drive inflammation. [2]

For patients, this is mainly "early research" that may help explain why some people with hypophosphatasia also report inflammatory or autoimmune conditions. It does not show that hypophosphatasia causes immune-mediated inflammatory diseases, and it cannot predict who will develop them, but it does add evidence that the enzyme involved in hypophosphatasia is reduced on immune cells and that inflammatory diagnoses were common in this particular group. What remains uncertain is how often this pattern appears in other countries and care settings, and whether these immune findings relate to symptoms, severity, or specific gene variants. Over time, this line of research may matter for understanding diagnosis patterns and the full range of hypophosphatasia-related health issues.

This month strengthened the message that hypophosphatasia often involves teeth and supporting tissues, and that these problems can vary by genetic variant and life stage. Laboratory research in mice showed variant-specific differences in enamel, dentin, and the bone around teeth, which helps explain why dental experiences can differ across families. A German dental guideline emphasized long-term, interdisciplinary planning for rare genetic dental disorders that include hypophosphatasia. Separately, a patient survey showed broad support for researching in-utero enzyme replacement for life-threatening hypophosphatasia, alongside strong concerns about safety and unknown long-term effects. [3] [4] [5]

In CRISPR knock-in mice carrying hypophosphatasia-linked ALPL variants, researchers observed genotype-dependent dental and periodontal changes, including reduced mineralization in tooth layers and lower mineral density in the jawbone around teeth. Both modeled variant groups showed signs of more fragile periodontal tissues, and the severity of dental changes was not fully explained by the level of alkaline phosphatase in the blood. For families, this supports the idea that local tooth and gum effects may have their own biology, which could help explain why dental issues can be prominent even when other bone findings seem mild. [3]

The German S3 dental guideline compiled 41 recommendations across diagnosis, prevention, restorative and prosthetic care, orthodontics, and surgery for rare dental disorders, including hypophosphatasia. It highlighted the need for age-appropriate long-term planning and coordination across disciplines, and it included genetic testing and counseling as part of establishing a precise diagnosis when appropriate. The guideline also noted that the evidence base is often low quality, reflecting how hard it is to run large studies in rare dental conditions, which helps set expectations about why dental decisions can vary between care systems. [4]

In a survey of 92 adults with lived experience of hypophosphatasia, most supported making in-utero enzyme replacement therapy available for life-threatening disease after prenatal detection and supported further research. People also voiced concerns about risks to the baby or mother, long-term side effects, and uncertainty about whether it would work, and they anticipated barriers such as financial burden. For affected families, this captures the real-world tradeoffs people consider when a potential treatment is very early and the stakes are high. [5]

For patients and caregivers, the dental guideline may matter now as a reference point for what comprehensive dental care planning can include, even though the guideline acknowledges that strong evidence is limited in many areas. The mouse research does not predict an individual person's outcome, but it adds a clearer explanation for why dental and gum problems may differ by genetic variant and may not match what blood tests show. The survey on in-utero enzyme replacement does not provide results on safety or effectiveness, but it clarifies that many in the community support research while still worrying about unknowns and cost. What remains uncertain is how these pieces will translate into better-proven dental approaches and earlier-life treatments, since several findings are still at the research stage.

This month included a single case report that connects hypophosphatasia with a possible orthopedic complication after joint replacement, but it cannot show how common this is. The report described repeated aseptic loosening (loosening not explained by infection) after total knee arthroplasty in a person with hypophosphatasia. It matters mainly as a signal that bone and mineralization differences in hypophosphatasia might be relevant in some surgical settings, which could be studied more carefully in larger groups. [6]

The authors specifically questioned whether hypophosphatasia contributed to the prosthetic failure, rather than concluding it was the cause. Because this is one person, it cannot separate hypophosphatasia-related risk from other reasons knee replacements can loosen. Even so, it adds to the broader picture that hypophosphatasia can involve bone strength and remodeling in ways that may matter beyond fractures, especially when bone needs to bond with an implant. [6]

For patients, this report is best viewed as a starting point for research, not a prediction about what will happen to others. It does not change how knee replacement outcomes should be expected in general, and it does not provide a rate of risk. What it does clarify is that researchers are paying attention to how hypophosphatasia-related bone biology might interact with orthopedic implants, which could lead to better evidence in the future. The main uncertainty is whether this experience reflects a broader pattern in hypophosphatasia or an individual outcome.